JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained what it got wrong forecasting GLP-1 drug demand.